anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A proteinaceous substance is rendered less soluble or less dispersible in an aqueous liquid by adding to said liquid with the proteinaceous substance dissolved or colloidally dispersed therein, polyethylene glycol having a molecular weight of at least 300 to precipitate at least some of said proteinaceous substance. The proteins may be mixed and fractional precipitation of the proteins is brought about by the addition of the polyethylene glycol.  Aqueous polyethylene glycol of suitable concentration may be used for selective elution of precipitated protein fractions. The average molecular weight of the polyethylene glycol may be up to 100,000. The temperature may be from 0 DEG  to 40 DEG  C. and the process may be used in conjunction with pH control and inorganic salt precipitation.  Examples relate to the fractionation of human blood plasma and the purification of Clostridium Novyi toxin, Botulinus Toxin type D, Tetanus anti-toxin, pancreatic desoxyribonuclease, fibrinogen and gamma globulin.  In general, the process is applicable to the separation, isolation and purification of plasma proteins, anti-toxins, bacterial toxins, viruses, nucleic acid and enzymes.ALSO:A proteinaceous substance is rendered less soluble or less dispersable in an aqueous liquid by adding to said liquid with the proteinaceous substance dissolved or colloidally dispersed therein, polyethylene glycol having a molecular weight of at least 300 to precipitate at least some of said proteinaceous substance. The proteins may be mixed and fractional precipitation of the proteins is brought about by the addition of the polyethylene glycol. Aqueous polyethylene glycol of suitable concentration may be used for selective elution of precipitated protein fractions.  The average molecular weight of the polyethylene glycol may be up to 100,000. The temperature may be from 0 DEG C to 40 DEG C. and the process may be used in conjunction with pH control and inorganic salt precipitation.  Examples relate to the fractionation of human blood plasma and the purification of Clostridium Novyi toxin, Botulinus Toxin type D, Tetanus anti-toxin, pancreatic desoxyribonuclease, fibrinogen and gamma-globulin.  In general, the process is applicable to the separation, isolation and purification of plasma proteins, antitoxins, bacterial toxins, viruses, nucleic acid and enzymes.
The invention provides NGR targeted peptide of CD13 (aminopeptidase N) and application thereof. The NGR targeted peptide has the amino acid sequence of CNGRVSTNGRC. The invention also provides a fusion protein NGR-TNF (tumor necrosis factor) alpha. The NGR-TNF alpha is the fusion protein formed by the NGR targeted peptide and a TNF alpha. The targeted peptide NGR of the CD13 is designed and screened by a conventional histochemical staining method; and then the NGR peptide is fused with a human TNF alpha by a gene recombination method to obtain the fusion protein NGR-TNF alpha. Through a great amount of experimental analysis, people find that by the NGR-TNF alpha, the growth of tumor cell can be inhibited by inhibiting the growth of neovascularization in tumor in a targeted mode and the effect of resisting the tumor is achieved.
PURPOSE: In patients with jaw bone atrophy, dental implant therapy requires bone augmentation on the alveolar ridge. Common methods are autologous bone transplantation or bone substitutes. The latter technique is less surgically invasive because it does not require bone harvesting; however, blood supply from the surrounding tissues and local differentiation of osteoblasts are not guaranteed, so adequate bone regeneration for dental implant therapy is often not achieved. Therefore, at our hospital we introduced a bone regenerative medicine technique that uses adipose stem cells (ASCs) from adipose tissue. The new approach is less surgically invasive and appears to have a better effect on bone regeneration. The current retrospective study aimed to demonstrate the efficacy of ASC transplantation in patients who underwent alveolar ridge bone augmentation at our hospital.
METHODS: We compared medical records, postoperative radiographic findings, and histological results from patients treated between January 2018 and March 2022 by augmentation of the jaw bone with bone substitutes (carbonate apatite) mixed with ASCs (ASCs+ group) and those treated with bone substitutes (carbonate apatite) alone (ASCs- group).
RESULTS: After 6 months, the survival rate of augmented bone and the gray scale value in dental cone beam computed tomography (a bone density index) were significantly higher in the ASCs+ group than in the ASCs- group. Histological analysis at 6 months showed more adequate bone tissue regeneration in the ASCs+ group.
CONCLUSIONS: The findings suggest the effectiveness of using ASCs in bone augmentation on the alveolar ridge in patients with jaw bone atrophy.
Fifty patients will be included into the study. The study comprises 9 visits. The treatment period covers 6 months, preceded by a 2-week screening period and a 1 month run-in period. Patients are required to visit the investigator two times before the start of active treatment.

All patients who are qualified for this study will then be randomised by receiving their medication/introduction of dietary management using the standard simple randomization method.Group I patients will receive keto-/amino acid (Ketosteril) supplemented low protein diet during the active treatment period while Group II patients will receive non-supplemented low protein diet during the same period. The daily dose of keto-/amino acid for each Group I patient is one tablet every 5 kg body weight. The total daily dose will be divided into three times a day.
Amantadine hydrochloride is a drug used commonly in clinical practice at the Carolinas Rehabilitation for the treatment of mood and behavior changes following traumatic brain injury. Clinical observation suggests that the use of amantadine improves caregiver report of "irritability" though there are no studies to validate this observation. This study investigates the efficacy and side effect profile of amantadine hydrochloride given in 2 doses of 100 mgs each. Subjects are screened during regularly scheduled clinic appointments for the presence of irritability. If they are interested in possible participation in the study, they will be invited to meet with the research coordinator who will obtain informed consent. If the subject meets all the inclusion/exclusion requirements, they will leave clinic with study medication and begin taking the drug the next day. There will be a safety call between day 3 and 5 where the dose may be reduced to once per day. Follow-up assessment occurs at day 14 (by phone) and day 28 (in clinic). At study completion, the subject will have the opportunity to receive a prescription for amantadine as part of ongoing clinical care.
INTRODUCTION: Migraine is a common condition that can carry considerable risk to aeromedical duties. Because randomized controlled trials are not an appropriate method to evaluate flight safety risk for medical conditions that may cause subtle or sudden incapacitation, the determination of fitness-to-fly must be based on risk assessments informed by extrapolated evidence. Therefore, we conducted a review of current literature to provide background information to inform the aeromedical risk assessment of migraine using a risk matrix approach.METHODS: We identified studies on topics pertinent to conducting an aeromedical risk assessment of migraine. We generated an overview of the literature synthesizing the findings of articles retrieved from searches of Scopus, Ovid, PubMed, and the Cochrane Library published in English from all years, in both general and aircrew populations. International headache and neurology guidelines, as well as headache policies from the U.S. Air Force, were also reviewed.RESULTS: This review includes information on the following topics relevant to conducting an evidence-based risk assessment of migraine: diagnosis, prevalence, incidence, natural course, clinical presentation, triggers, comorbidities, neuroimaging, implications of family history, and efficacy of pharmacological and nonpharmacological therapies.DISCUSSION: This review summarizes current literature on migraine for use in a risk matrix approach to the aeromedical assessment of migraine in prospective and current aircrew. Awareness of the most current epidemiological data related to a variety of migraine parameters facilitates an evidence-based risk assessment of migraine in aircrew and requires iterative updates as new information becomes available.Mainland RL, Skinner CR, Saary J. Aeromedical risk of migraine. Aerosp Med Hum Perform. 2024; 95(2):101-112.
<P>PROBLEM TO BE SOLVED: To provide a stimulation-responsive cross-linked protein micell containing a cross-linked protein structure body.  <P>SOLUTION: The protein constituting the structure body preferably has an aspartic acid residue or a glutamic acid residue and a lysin residue; and the cross-linkage is preferably formed by a condensation reaction of -COOH group of the aspartic acid residue or a glutamic acid residue with -NH<SB>2</SB>group of the lysin residue or the N-terminal. Particularly preferable example of the protein used is β-casein. This cross-linked protein micell has an inherent lower critical solution temperature (LCST) at which it causes a soluble phenomenon at a low temperature side and causes an insoluble phenomenon at a high temperature side making a specific temperature as a border. In this stimulation-responsive cross-linked protein micell, application in bioseparation, biosensing, immobilized enzyme and drug delivery system is expected.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Group C did not receive any medication; after the two-month study period, the clinical periodontal parameters were reassessed. Additionally, to compare the total antioxidant capacity in saliva before and after the intake of these supplements, as well as in patients who did not receive any medication, 2 ml of non-stimulated saliva was collected from each participant at the beginning and end of the study for analysis using UV-spectrophotometric methods, furthermore, the following criteria determined the selection of eligible participants for this study.
FIELD: medicine. SUBSTANCE: invention relates to methods of preparing the dried extracts of vegetable raw. Method involves extraction of raw and separation of extracts from the oil cake. Extraction is carried out with oil and an aqueous-alcoholic mixture or fat and an aqueous-alcoholic mixture simultaneously at the following ratio of components: dried vegetable raw 1; oil or fat 3-40; ethyl alcohol 1.5-15 and water 3-30. Then a mixture is cooled before the stage of the oil cake separation and phases are separated. Saint-John's-wort herb and flowers or pot-marigold flowers are used as the dried vegetable raw. Corn or soybean oil is used as oil and pig fat is used as fat. EFFECT: increased yield and improved extraction of biologically active components of raw. 7 cl, 2 tbl
Following the first relapse, patients with follicular type of Non-Hodgkin's lymphoma may have an option to receive high dose chemotherapy followed by autologous (from you) blood stem cell transplantation. One of the common causes of relapse is persistence of lymphoma cells in the bone marrow and in the collected stem cell products.

Patients who do not have a complete response after traditional chemotherapy, have a greater chance of the lymphoma returning even after receiving high dose chemotherapy with stem cell transplantation. In order to improve the response and decrease the relapse rate, additional therapy may be used to kill the lymphoma cells by using antibodies both before and after the transplantation. Antibodies are protein made by white cells in our body to fight off infection and sometimes tumor. Rituxan (rituximab) is an antibody that is effective against your type of lymphoma. Researchers have reported that patients show an improved response and a lower chance of relapse when using rituximab with high dose chemotherapy with autologous stem cell transplantation. It is unknown how effective rituximab is in clearing persistence of minimal remaining disease in patients with follicular lymphoma.
The recommended dosage of STROMECTOL for the treatment of strongyloidiasis is a single oral dose designed to provide approximately 200 mcg of ivermectin per kg of body weight. See Table 1 for dosage guidelines. Patients should take tablets on an empty stomach with water. (See CLINICAL PHARMACOLOGY, Pharmacokinetics.) In general, additional doses are not necessary. However, follow-up stool examinations should be performed to verify eradication of infection. (See CLINICAL PHARMACOLOGY, Clinical Studies.)
The invention relates to the technical field of biological medicine, in particular to application of a plant to the production of oral somaglutide and lumbrokinase hypoglycemic capsules. The present invention utilizes plants such as lettuce as an efficient expression platform for recombinant protein production, and utilizes a simple and efficient expression system to produce bioactive substances. The leaves from which the active substance is produced are subsequently freeze-dried to form capsules. The capsule can be preserved at room temperature while maintaining biological activity. And determining the successful expression of the hypoglycemic active protein by using a Western Blot protein hybridization method. The biological activity test result shows that the blood sugar reducing capsule produced by the platform technology obviously reduces the blood sugar concentration of the dog blood.
Patients who decline to undergo an LP with VR will be asked if they would be willing to participate by answering questionnaires specific to their pre procedure anxiety. This will include questionnaires 2 and 3 from above. The investigators will also plan to collect vital sign data if they agree to participate in that capacity.
Placebo capsule ( (n=16), (EPA=0 mg, DHA=0 mg)). The duration of the intervention was 8 weeks.
Obesity in the pediatric population is a primary public health concern given that overweight and obesity in childhood continues into adulthood. Consumption of high-fat, calorie-dense diets do not provide individuals with the suggested daily intake of many important nutrients. This is especially true for dietary fiber which has positive health benefits such as roles in weight management. A form of dietary fiber with links to obesity treatment/prevention is prebiotic fiber. In the gut, there are many bacteria which have been shown to affect a person's health depending on the type and number of each type of bacteria. The role of prebiotic fiber is to increase the number of beneficial bacteria which in turn promotes health. Studies in humans have shown that prebiotic fiber is effective at reducing body fat and food intake in overweight and obese adults. The aim of this study is to see if prebiotic fiber can provide the same benefits to overweight and obese children. Since weight management becomes increasingly difficult as a person ages, treatments that promote weight maintenance at an early age are critically needed.
Structured treatment interruptions (STIs) may stimulate an anti-HIV immune response. Evidence suggests that IL-2, which increases CD4 counts, could also enhance specific immune responses to HIV. Enhanced immune responses could influence the magnitude of and the time to virologic rebound following treatment discontinuation. This study will compare the viral loads present after 12 weeks of an antiretroviral therapy (ART) interruption period between patients who have received different dosing regimens of IL-2 and have taken part in at least two STIs.

This study will last 40 to 104 weeks. IL-2 is provided as part of this study; potent ART is not provided. Patients in this study will receive potent ART with at least two scheduled potent ART interruptions. Patients will be randomly assigned to one of two treatment arms. Arm A patients will receive low-dose injections of IL-2 for 3 weeks, during the last 2 weeks of potent ART interruption periods and the first week of restarting potent ART. Arm B patients will receive high-dose injections of IL-2 during the first 5 days of restarting potent ART after the interruption period. The first two ART interruptions are 4 weeks in duration, followed by 12 weeks back on ART. Depending on the patient's viral load and CD4 count at Week 32, patients will either enter a third potent ART interruption for 12 to 48 weeks or will continue ART. No IL-2 will be given with the third scheduled potent ART interruption. Throughout the study, participants will have physical exams and laboratory tests, including measurements of viral load and CD4 count.
Patellofemoral Pain (PFP) is characterized by pain localized in the peripatellar or retropatellar regions in young and physically active individuals . In patients with PFP, during single-leg squatting, an increase in the valgus of the knee joint due to hip abductor muscle weakness and in the internal rotation of the femur due to weakness of the hip external rotators and abductor muscles are observed. Theoretically it has been shown that faulty hip kinematics can increase lateral loading in the patellofemoral joint. Therefore, conducting exercises to strengthen the extensor, external rotator, and abductor muscles of the hip and lateral flexor muscles of the trunk are an important treatment approaches. Strengthening the quadriceps muscle is a widely used method of treating PFP. Previous studies suggest that hip and trunk exercises prescribed in combination with traditional quadriceps strengthening exercises are effective in reducing pain and improving function in patients with PFP .

In recent years, kinesiotape is one of the widely used methods in the treatment of PFP. The correction of the abnormal patellar displacement, the reduction of the patellofemoral joint reaction forces, and the regulation of the activation of the vastus medialis muscle is provided with patellar taping. Patellar taping is recommended as part of evidence-based combined physiotherapy programs in the treatment of PFP . Increased pronation of the subtalar joint and the decrease / flattening of the medial arch height are associated with PFP. Prolonged pronation time is observed in subtalar and midtarsal joints during gait. To correct increased pronation, foot orthoses, low-dye taping and kinesio taping are applied . The effect of kinesiotaping on foot pronation, however, is unclear due to the lack of published studies.

To our knowledge, although patellar taping is applied in patients with PFP no studies have examined the effects of kinesiotaping supporting the medial arch and allowing forefoot and hind foot to move within the normal range. The aim of this study was to investigate the effects of corrective kinesio taping applied on patellofemoral joint and foot in addition to a progressive neuromuscular exercise program in women with Patellofemoral Pain on knee pain and muscle strength.
Gut fungal imbalances, particularly increased Candida spp., are linked to obesity. This study explored the potential of Lactiplantibacillus plantarum cell-free extracts (postbiotics) to modulate the growth of Candida albicans and Candida kefyr, key members of the gut mycobiota. A minimal synthetic gut model was employed to evaluate the effects of Lactiplantibacillus plantarum postbiotics on fungal growth in mono- and mixed cultures. Microreactors were employed for culturing, fungal growth was quantified using CFU counting, and regression analysis was used to evaluate the effects of postbiotics on fungal growth. Postbiotics at a concentration of 12.5% significantly reduced the growth of both Candida species. At 24 h, both C. albicans and C. kefyr in monocultures exhibited a decrease in growth of 0.11 log CFU/mL. In contrast, mixed cultures showed a more pronounced antifungal effect, with C. albicans and C. kefyr reductions of 0.62 log CFU/mL and 0.64 log CFU/mL, respectively. Regression analysis using the Gompertz model supported the antifungal activity of postbiotics and revealed species-specific differences in growth parameters. These findings suggest that L. plantarum postbiotics have the potential to modulate the gut mycobiota by reducing Candida growth, potentially offering a therapeutic approach for combating fungal overgrowth associated with obesity.
OBJECTIVE: Dyspnea, or breathlessness, is an important symptom in amyotrophic lateral sclerosis/motor neuron disease (ALS/MND). We examined the measurement properties of the Dyspnea-12.
METHODS: Rasch analysis enabled conversion of raw Dyspnea-12 scores to interval level metric equivalents. Converted data were used to perform trajectory modeling; those following different trajectories were compared for demographic, clinical, symptom, and functioning characteristics. Logistic regression examined differences between distinct trajectories.
RESULTS: In 1022 people, at baseline, mean metric Dyspnea-12 was 7.6 (SD 9.3). 49.8% had dyspnea, severe in 12.6%. Trajectory analysis over 28 months revealed three breathlessness trajectories: group 1 reported none at baseline/follow-up (42.7%); group 2 significantly increased over time (9.4%); group 3 had a much higher level at baseline which rose over follow-up (47.9%). Group 3 had worse outcomes on all symptoms, functioning and quality of life; compared to group 1, their odds of: respiratory onset sixfold greater; King's stage ≥3 2.9 greater; increased odds of being bothered by choking, head drop, fasciculations, and muscle cramps; fatigue and anxiety also elevated (p < .01).
CONCLUSION: Dyspnea is a cardinal symptom in ALS/MND and can be quickly measured using the Dyspnea-12. Raw scores can easily be converted to interval level measurement, for valid change scores and trajectory modeling. Dyspnea trajectories reveal different patterns, showing that clinical services must provide monitoring which is customized to individual patient need. Almost half of this large population had worsening dyspnea, confirming the importance of respiratory monitoring and interventions being integrated into routine ALS care.
The need to maintain a proper depth of general anesthesia during pediatric surgery is an important aspect of anesthesiology. An inappropriate anesthesia depth increases the risk of intraoperative awareness or delay in recovery in children undergoing surgery. Current modalities for anesthesia depth monitoring showed limited accuracy in children. The electroencephalogram (EEG) can be analyzed in its raw form for characteristic drug-induced patterns of change or summarized using mathematical parameters as a processed electroencephalogram (pEEG). The change profiles of indices derived from pEEG such as phase-amplitude coupling and bicoherence based on individual general anesthetics in children have not been examined in previous literature. Whether those indices have the abilities to predict individual drug-related anesthesia depth in children need to be explored.
Participants will be involved in an integrated interorganisational fragility fracture prevention program, which combines both post-fracture management as well as fall prevention strategies. The intervention will last up to 18 months.
Echolocating big brown bats (Eptesicus fuscus) broadcast downward frequency-modulated sweeps covering the ultrasonic range from 100-23 kHz in two harmonics. They perceive target range from the time delay between each broadcast and its returning echo. Previous experiments indicated that the bat's discrimination acuity for broadcast-echo delay declines when the lowest frequencies (23-35 kHz) in the first harmonic of an echo are removed. This experiment examined whether echo detection is similarly impaired. Results show that detection thresholds for echoes missing these lowest frequencies are raised. Increased thresholds for echoes differing in spectra facilitates the bat's ability to discriminate against clutter.